Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
SmartLabs and Sonrai Launch Exclusive Partnership to Bring Advanced AI Capabilities to SmartLabs' Member Companies
Friday, August 29, 2025SmartLabs and Sonrai Analytics Sonrai today announced a global strategic partnership designed to bring Sonrais nextgeneration AI capabilities directly into SmartLabs network of advanced research centers
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
Friday, August 29, 2025Camurustoday announced that the UK Medicines and Healthcare products Regulatory Agency MHRA has approved Oczyesa octreotide subcutaneous depot marketing authorization for the maintenance treatment
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Thursday, August 28, 2025Pfizer Incand BioNTech SE today announced the US Food and Drug Administration FDA has approved the supplemental Biologics License Application sBLA for the companies LPadapted monovalent COVID vaccine
Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Thursday, August 28, 2025Heidelberg Pharma AG a clinical stage biotech company developing innovative Antibody Drug Conjugates ADCs today announced that its licensing partner Telix Pharmaceuticals Limited headquartered in Melbourne Australia
Leqembi® (lecanemab) launched in the EU today
Tuesday, August 26, 2025BioArctic ABs publ NASDAQ Stockholm BIOA B partner Eisai announced today that the launch of Leqembi in the EU started in Austria on August and will be launched in Germany on September
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for VG801 Gene Therapy for Stargardt Disease
Friday, August 22, 2025VeonGen Therapeutics a clinicalstage genetic medicine company developing nextgeneration gene therapies today announced that the US Food and Drug Administration FDA has granted Regenerative Medicine Advanced Therapy
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
Thursday, August 21, 2025Regeneron Pharmaceuticals Inctoday announced that the US Food and Drug Administration FDA has extended the target action dates to the fourth quarter of for two EYLEA HD aflibercept Injection
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
Thursday, August 21, 2025Rocket Pharmaceuticals Inca fully integrated latestage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need today announced that the US Food and Drug Administration
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Wednesday, August 20, 2025Santhera Pharmaceuticalsannounces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE vamorolone in the United Arab Emirates the Kingdom of Saudi Arabia Kuwait
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
Wednesday, August 20, 2025Aldeyra Therapeutics Inctoday announced that the US Food and Drug Administration FDA has granted fast track designation for ADX methotrexate intravitreal injection USP for the treatment of retinitis pigmentosa
